An Updated Critical Analysis of the Treatment Strategy for Newly Diagnosed High-grade T1 (Previously T1G3) Bladder Cancer

European Urology

Volumn 57, Issue 1, 2010, Pages 60-70

  Kulkarni, Girish S ^a   Hakenberg, Oliver W ^b   Gschwend, Juergen E ^c   Thalmann, George ^d   Kassouf, Wassim ^e   Kamat, Ashish ^f   Zlotta, Alexandre ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF ROSTOCK   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF BERN   (Switzerland)

^e MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

BCG; Bladder Cancer; Cystectomy; High grade; T1; T1G3; Treatment

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; GEMCITABINE; MITOMYCIN C;

ALGORITHM; BLADDER CANCER; CANCER GRADING; CANCER STAGING; CLINICAL TRIAL; CYSTECTOMY; DRUG CHOICE; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENCE RISK; RECURRENT CANCER; REVIEW; RISK ASSESSMENT; RISK FACTOR; TRANSURETHRAL RESECTION; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INTRAVESICAL; ALGORITHMS; ANTINEOPLASTIC AGENTS; BCG VACCINE; CHEMOTHERAPY, ADJUVANT; CYSTECTOMY; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; HUMANS; LYMPHATIC METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PATIENT SELECTION; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 70449526527     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.08.024     Document Type: Review

References (90)

1. Tyczynski JE, Parkin DM. Bladder cancer in Europe. European Network of Cancer Registries Web site. http://www.encr.com.fr/bladder-factsheets.pdf. Updated September 2003. Accessed December 10, 2008.
2. van Rhijn B.W.G., Burger M., Lotan Y., et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol 56 (2009) 430-442
3. Cookson M.S., Herr H.W., Zhang Z.F., Soloway S., Sogani P.C., and Fair W.R. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 158 (1997) 62-67
4. Philips B, Ball C, Sackett D, et al. Oxford Centre for Evidence-Based Medicine: levels of evidence. Centre for Evidence-Based Medicine Web site. http://www.cebm.net/index.aspx?o=1025. Updated March 2009. Accessed August 5, 2009.
5. van der Meijden A.P. The use of the marker tumor concept in Ta, T1 bladder cancer: is it justified?. Urol Oncol 7 (2002) 31-33
6. Witjes J.A., and Douglass J. The role of hexaminolevulinate fluorescence cystoscopy in bladder cancer. Nat Clin Pract Urol 4 (2007) 542-549
7. Dutta S.C., Smith Jr. J.A., Shappell S.B., Coffey C.S., Chang S.S., and Cookson M.S. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol 166 (2001) 490-493
8. Herr H.W. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 162 (1999) 74-76
9. Jakse G., Algaba F., Malmström P.-U., and Oosterlinck W. A second-look TUR in T1 transitional cell carcinoma: why?. Eur Urol 45 (2004) 539-546
10. Van Der Meijden A., Sylvester R., Collette L., Bono A., and Ten Kate F. The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer Trials. J Urol 164 (2000) 1533-1537
11. Epstein J.I. The new World Health Organization/International Society of Urological Pathology (WHO/ISUP) classification for TA, T1 bladder tumors: is it an improvement?. Crit Rev Oncol Hematol 47 (2003) 83-89
12. Harnden P. A critical appraisal of the classification of urothelial tumours: time for a review of the evidence and a radical change?. BJU Int 99 (2007) 723-725
13. Burger M., Denzinger S., Wieland W.F., Stief C.G., Hartmann A., and Zaak D. Does the current World Health Organization classification predict the outcome better in patients with noninvasive bladder cancer of early or regular onset?. BJU Int 102 (2008) 194-197
14. Burger M., van der Aa M.N.M., van Oers J.M.M., et al. Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. Eur Urol 54 (2008) 835-844
15. Kirkali Z., Chan T., Manoharan M., et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 66 (2005) 4-34
16. Brausi M., Collette L., Kurth K., et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 41 (2002) 523-531
17. Sylvester R.J., Oosterlinck W., and van der Meijden A.P. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 171 (2004) 2186-2190
18. Berrum-Svennung I., Granfors T., Jahnson S., Boman H., and Holmang S. A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences. J Urol 179 (2008) 101-105
19. Miladi M., Peyromaure M., Zerbib M., Saïghi D., and Debré B. The value of a second transurethral resection in evaluating patients with bladder tumours. Eur Urol 43 (2003) 241-245
20. Schwaibold H.E., Sivalingam S., May F., and Hartung R. The value of a second transurethral resection for T1 bladder cancer. BJU Int 97 (2006) 1199-1201
21. Brauers A., Buettner R., and Jakse G. Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early?. J Urol 165 (2001) 808-810
22. Soloway M.S., Lee C.T., Steinberg G.D., Ghandi A.A., and Jewett M.A. Difficult decisions in urologic oncology: management of high-grade T1 transitional cell carcinoma of the bladder. Urol Oncol 25 (2007) 338-340
23. Divrik T., Yildirim U., Eroglu A.S., Zorlu F., and Ozen H. Is a second transurethral resection necessary for newly diagnosed pT1 bladder cancer?. J Urol 175 (2006) 1258-1261
24. Herr H.W., Donat S.M., and Dalbagni G. Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy?. J Urol 177 (2007) 75-79
25. Shelley MD, Court JB, Kynaston H, Wilt TJ, Fish RG, Mason M. Intravesical bacillus Calmette-Guerin in Ta and T1 bladder cancer. Cochrane Database Syst Rev 2000:CD001986.
26. Sylvester R.J., van der Meijden A.P., and Lamm D.L. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168 (2002) 1964-1970
27. Bohle A., Jocham D., and Bock P.R. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169 (2003) 90-95
28. Shelley M.D., Wilt T.J., Court J., Coles B., Kynaston H., and Mason M.D. Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 93 (2004) 485-490
29. Bohle A., and Bock P.R. Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 63 (2004) 682-686
30. Serretta V., Pavone C., Ingargiola G.B., Daricello G., Allegro R., and Pavone-Macaluso M. TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years. Eur Urol 45 (2004) 730-736
31. Cheng C.W., Ng M.T., Chan S.Y., and Sun W.H. Low dose BCG as adjuvant therapy for superficial bladder cancer and literature review. ANZ J Surg 74 (2004) 569-572
32. Hurle R., Losa A., Ranieri A., Graziotti P., and Lembo A. Low dose Pasteur bacillus Calmette-Guerin regimen in stage T1, grade 3 bladder cancer therapy. J Urol 156 (1996) 1602-1605
33. Lebret T., Gaudez F., Hervé J.-M., Barré P., Lugagne P.-M., and Botto H. Low-dose BCG instillations in the treatment of stage T1 grade 3 bladder tumours: recurrence, progression and success. Eur Urol 34 (1998) 67-72
34. Martinez-Pineiro J.A., Flores N., Isorna S., et al. Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int 89 (2002) 671-680
35. Yoneyama T., Ohyama C., Imai A., et al. Low-dose instillation therapy with bacille Calmette-Guerin Tokyo 172 strain after transurethral resection: historical cohort study. Urology 71 (2008) 1161-1165
36. Lamm D.L., Blumenstein B.A., Crissman J.D., et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163 (2000) 1124-1129
37. Herr H.W. Is maintenance Bacillus Calmette-Guérin really necessary?. Eur Urol 54 (2008) 971-973
38. Decobert M., LaRue H., Harel F., Meyer F., Fradet Y., and Lacombe L. Maintenance bacillus Calmette-Guerin in high-risk nonmuscle-invasive bladder cancer: how much is enough?. Cancer 113 (2008) 710-716
39. Dalbagni G., and Herr H.W. Current use and questions concerning intravesical bladder cancer group for superficial bladder cancer. Urol Clin North Am 27 (2000) 137-146
40. Brake M., Loertzer H., Horsch R., and Keller H. Long-term results of intravesical bacillus Calmette-Guerin therapy for stage T1 superficial bladder cancer. Urology 55 (2000) 673-678
41. Catalona W.J., Hudson M.A., Gillen D.P., Andriole G.L., and Ratliff T.L. Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol 137 (1987) 220-224
42. Soloway M.S., Sofer M., and Vaidya A. Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol 167 (2002) 1573-1583
43. Raj G.V., Herr H., Serio A.M., et al. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol 177 (2007) 1283-1286
44. Nieder A.M., Brausi M., Lamm D., et al. Management of stage T1 tumors of the bladder: International Consensus Panel. Urology 66 (2005) 108-125
45. Joudi F.N., Smith B.J., O'Donnell M.A., and National BCG-Interferon Phase 2 Investigator Group. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 24 (2006) 344-348
46. Dalbagni G., Russo P., Bochner B., et al. Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder. J Clin Oncol 24 (2006) 2729-2734
47. Bartoletti R., Cai T., Gacci M., et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study. Urology 66 (2005) 726-731
48. Gunelli R., Bercovich E., Nanni O., et al. Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study. Br J Cancer 97 (2007) 1499-1504
49. van der Heijden A.G., Kiemeney L.A., Gofrit O.N., et al. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol 46 (2004) 65-72
50. Di Stasi S.M., Giannantoni A., Giurioli A., et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol 7 (2006) 43-51
51. Dalbagni G., Herr H.W., and Reuter V.E. Impact of a second transurethral resection on the staging of T1 bladder cancer. Urology 60 (2002) 822-824
52. Birkmeyer J.D., Siewers A.E., Finlayson E.V., et al. Hospital volume and surgical mortality in the United States. N Engl J Med 346 (2002) 1128-1137
53. Stein J.P., Lieskovsky G., Cote R., et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19 (2001) 666-675
54. Kulkarni G.S., Finelli A., Fleshner N.E., Jewett M.A., Lopushinsky S.R., and Alibhai S.M. Optimal management of high-risk T1G3 bladder cancer: a decision analysis. PLoS Med 4 (2007) e284
55. Wiesner C., Pfitzenmaier J., Faldum A., Gillitzer R., Melchior S.W., and Thuroff J.W. Lymph node metastases in non-muscle invasive bladder cancer are correlated with the number of transurethral resections and tumour upstaging at radical cystectomy. BJU Int 95 (2005) 301-305
56. Herr H.W., and Sogani P.C. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?. J Urol 166 (2001) 1296-1299
57. Denzinger S., Fritsche H.-M., Otto W., Blana A., Wieland W.-F., and Burger M. Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach?. Eur Urol 53 (2008) 146-152
58. Lambert E.H., Pierorazio P.M., Olsson C.A., Benson M.C., McKiernan J.M., and Poon S. The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy. BJU Int 100 (2007) 33-36
59. Sylvester R.J., van der Meijden A.P.M., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49 (2006) 466-477
60. Dalbagni G., Parekh D.J., Ben-Porat L., Potenzoni M., Herr H.W., and Reuter V.E. Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder. BJU Int 99 (2007) 281-285
61. Grossman H.B., Liebert M., Antelo M., et al. p53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res 4 (1998) 829-834
62. Weiss C., Wolze C., Engehausen D.G., et al. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy?. J Clin Oncol 24 (2006) 2318-2324
63. Harland S.J., Kynaston H., Grigor K., et al. A randomized trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder. J Urol 178 (2007) 807-813
64. Zhang G.K., Uke E.T., Sharer W.C., Borkon W.D., and Bernstein S.M. Reassessment of conservative management for stage T1N0M0 transitional cell carcinoma of the bladder. J Urol 155 (1996) 1907-1909
65. Herr H.W. Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome. Br J Urol 80 (1997) 762-765
66. Hurle R., Losa A., Manzetti A., and Lembo A. Intravesical bacille Calmette-Guerin in stage T1 grade 3 bladder cancer therapy: a 7-year follow-up. Urology 54 (1999) 258-263
67. Gohji K., Nomi M., Okamoto M., et al. Conservative therapy for stage T1b, grade 3 transitional cell carcinoma of the bladder. Urology 53 (1999) 308-313
68. Brake M., Loertzer H., Horsch R., and Keller H. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin. J Urol 163 (2000) 1697-1701
69. Patard J., Moudouni S., Saint F., et al. Tumor progression and survival in patients with T1G3 bladder tumors: multicentric retrospective study comparing 94 patients treated during 17 years. Urology 58 (2001) 551-556
70. Pansadoro V., Emiliozzi P., de Paula F., Scarpone P., Pansadoro A., and Sternberg C.N. Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guerin: 18-year experience. Urology 59 (2002) 227-231
71. Iori F., Di Seri M., De Nunzio C., et al. Long-term maintenance bacille Calmette-Guerin therapy in high-grade superficial bladder cancer. Urology 59 (2002) 414-418
72. Kulkarni J.N., and Gupta R. Recurrence and progression in stage T1G3 bladder tumour with intravesical bacille Calmette-Guerin (Danish 1331 strain). BJU Int 90 (2002) 554-557
73. Griffiths T.R., Charlton M., Neal D.E., and Powell P.H. Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance. J Urol 167 (2002) 2408-2412
74. Shahin O., Thalmann G.N., Rentsch C., Mazzucchelli L., and Studer U.E. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol 169 (2003) 96-100
75. Hara I., Miyake H., Takechi Y., et al. Clinical outcome of conservative therapy for stage T1, grade 3 transitional cell carcinoma of the bladder. Int J Urol 10 (2003) 19-24
76. Peyromaure M., Guerin F., Amsellem-Ouazana D., Saighi D., Debre B., and Zerbib M. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients. J Urol 169 (2003) 2110-2112
77. Peyromaure M., and Zerbib M. T1G3 transitional cell carcinoma of the bladder: recurrence, progression and survival. BJU Int 93 (2004) 60-63
78. Baniel J., Grauss D., Engelstein D., and Sella A. Intravesical bacillus Calmette-Guerin treatment for Stage T1 grade 3 transitional cell carcinoma of the bladder. Urology 52 (1998) 785-789
79. Margel D., Tal R., Golan S., Kedar D., Engelstein D., and Baniel J. Long-term follow-up of patients with Stage T1 high-grade transitional cell carcinoma managed by bacille Calmette-Guerin immunotherapy. Urology 69 (2007) 78-82
80. Thalmann G.N., Markwalder R., Shahin O., Burkhard F.C., Hochreiter W.W., and Studer U.E. Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy?. J Urol 172 (2004) 70-75
81. Masood S., Sriprasad S., Palmer J.H., and Mufti G.R. T1G3 bladder cancer-indications for early cystectomy. Int Urol Nephrol 36 (2004) 41-44
82. Bianco Jr. F.J., Justa D., Grignon D.J., Sakr W.A., Pontes J.E., and Wood Jr. D.P. Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy. Urol Oncol 22 (2004) 290-294
83. Gupta A., Lotan Y., Bastian P.J., et al. Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy. Urology 71 (2008) 302-307
84. Divrik R.T., Sahin A., Altok M., Unlu N., and Zorlu F. The frequency of hydronephrosis at initial diagnosis and its effect on recurrence and progression in patients with superficial bladder cancer. J Urol 178 (2007) 802-806
85. Bernardini S., Billerey C., Martin M., Adessi G.L., Wallerand H., and Bittard H. The predictive value of muscularis mucosae invasion and p53 overexpression on progression of stage T1 bladder carcinoma. J Urol 165 (2001) 42-46
86. Orsola A., Trias I., Raventós C.X., et al. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients. Eur Urol 48 (2005) 231-238
87. Herr H.W., and Donat S.M. A re-staging transurethral resection predicts early progression of superficial bladder cancer. BJU Int 97 (2006) 1194-1198
88. Holmang S., and Johansson S.L. Stage Ta-T1 bladder cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression. J Urol 167 (2002) 1634-1637
89. Solsona E., Iborra I., Dumont R., Rubio-Briones J., Casanova J., and Almenar S. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol 164 (2000) 685-689
90. Huguet J., Crego M., Sabaté S., Salvador J., Palou J., and Villavicencio H. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. Eur Urol 48 (2005) 53-59